Radioimmunotherapy of Colorectal Cancer in Small Volume Disease: Preclinical Evaluation in Comparison to Equitoxic Chemotherapy and Preliminary Results of an Ongoing Phase-I/II Clinical Trial

1999 ◽  
pp. 51-57
Author(s):  
T. M. Behr ◽  
S. Memtsoudis ◽  
V. Vougioukas ◽  
T. Liersch ◽  
S. Gratz ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trial ◽  
Phase I ◽  
Small Volume ◽  
Preclinical Evaluation ◽  
Preliminary Results ◽  
Ongoing Phase

Interstitial thermoradiotherapy of brain tumors: Preliminary results of a phase I clinical trial

1990 ◽  
Vol 19 (6) ◽  
pp. 1463-1471 ◽  
Author(s):  
Baldassarre Stea ◽  
Thomas C. Cetas ◽  
J. Robert^Cassady ◽  
A. Norman^Guthkelch ◽  
Robert Iacono ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Brain Tumors ◽  
Phase I ◽  
Phase I Clinical Trial ◽  
Preliminary Results

Two-fraction carbon ion radiotherapy for hepatocellular carcinoma: Preliminary results of a phase I/II clinical trial

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 4124-4124 ◽  
Author(s):  
H. Kato ◽  
S. Yamada ◽  
S. Yasuda ◽  
K. Yamaguchi ◽  
H. Kitabayashi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Trial ◽  
Phase I ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ion ◽  
Preliminary Results

Copper deficiency as an anti-cancer strategy.

2004 ◽  
Vol 11 (2) ◽  
pp. 255-263 ◽  
Author(s):  
V L Goodman ◽  
G J Brewer ◽  
S D Merajver
Keyword(s):  
Clinical Trial ◽  
Animal Models ◽  
Phase I ◽  
Copper Deficiency ◽  
Menkes Disease ◽  
Invasion And Metastasis ◽  
Anti Cancer ◽  
Copper Chelator ◽  
Ongoing Phase

Copper is a tightly regulated trace element. Disruptions of copper homeostasis are rare and they cause serious disorders such as Wilson's disease and Menkes disease. Copper also plays an important role in promoting physiological and malignant angiogenesis. Formation of new blood vessels by a tumor enables tumor growth, invasion and metastasis. The copper chelator tetrathiomolybdate (TM), which quickly and effectively depletes copper stores, is under investigation as an anti-angiogenic agent. Promising results in vitro, in pre-clinical animal models and in an early (phase I) clinical trial have led to ongoing phase II evaluation of TM in patients with advanced cancers.

Sign in / Sign up

Export Citation Format

Share Document